NeoGenomics, Inc. $NEO Stock Holdings Trimmed by White Pine Capital LLC

White Pine Capital LLC decreased its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 29.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,087 shares of the medical research company’s stock after selling 11,788 shares during the quarter. White Pine Capital LLC’s holdings in NeoGenomics were worth $205,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Brooklyn Investment Group bought a new stake in NeoGenomics in the first quarter valued at $35,000. CWM LLC lifted its position in NeoGenomics by 42.6% in the 1st quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 1,883 shares during the last quarter. AlphaQuest LLC bought a new stake in NeoGenomics in the 1st quarter valued at about $60,000. Capstone Financial Advisors Inc. acquired a new position in NeoGenomics during the 2nd quarter valued at about $73,000. Finally, Moors & Cabot Inc. grew its position in NeoGenomics by 20.0% in the 2nd quarter. Moors & Cabot Inc. now owns 12,000 shares of the medical research company’s stock worth $88,000 after purchasing an additional 2,000 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Price Performance

Shares of NEO opened at $11.48 on Friday. The business’s 50-day moving average is $9.51 and its 200-day moving average is $7.94. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.91 and a quick ratio of 3.58. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -13.05 and a beta of 1.67. NeoGenomics, Inc. has a fifty-two week low of $4.72 and a fifty-two week high of $19.11.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.The firm had revenue of $187.80 million during the quarter, compared to analysts’ expectations of $183.85 million. During the same quarter last year, the firm earned $0.05 earnings per share. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Equities research analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on NEO. BTIG Research reissued a “neutral” rating on shares of NeoGenomics in a research note on Wednesday, July 30th. Needham & Company LLC increased their target price on shares of NeoGenomics from $8.00 to $14.00 and gave the company a “buy” rating in a research report on Friday, August 29th. William Blair restated a “market perform” rating on shares of NeoGenomics in a research report on Tuesday, July 29th. Piper Sandler set a $11.00 price target on shares of NeoGenomics and gave the stock an “overweight” rating in a research note on Monday, August 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a report on Monday. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, NeoGenomics currently has an average rating of “Hold” and an average price target of $13.11.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.